Polyamines metabolism and breast cancer: state of the art and perspectives

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 233-248

  Cervelli, Manuela ^a   Pietropaoli, Stefano ^a   Signore, Fabrizio ^b   Amendola, Roberto ^c   Mariottini, Paolo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c ENEA   (Italy)

Author keywords

Breast cancer cell lines; Breast cancer treatment; Clinical trials; In vivo models; Polyamine metabolism

Indexed keywords

ACYLTRANSFERASE; EFLORNITHINE; MITOGUAZONE; N,N' BIS(3 BENZYLAMINOPROPYL) 1,7 HEPTANEDIAMINE; N1 ACETYLPOLYAMINE OXIDASE; N1 ACETYLSPERMIDINE; N1 ACETYLSPERMINE; N1 ETHYL N11 [(CYCLOHEPTYL)METHYL] 4,8 DIAZAUNDECANE; N1, N11 BIS(ETHYL)NORSPERMINE; N1, N12 BIS(ETHYL) 6,7 DEHYDROSPERMINE; N1,N12 DIACETYLSPERMINE; N1,N14 BIS(ETHYL)HOMOSPERMINE; ORNITHINE DECARBOXYLASE; OXIDOREDUCTASE; POLYAMINE DERIVATIVE; PUTRESCINE; ROSCOVITINE; SARDOMOZIDE; SPERMIDINE; SPERMIDINE SPERMINE N1 ACETYLTRANSFERASE; SPERMINE; SPERMINE OXIDASE; SULFONAMIDO OXASPERMIDINE; SULFONAMIDO OXASPERMINE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; POLYAMINE;

BIOSYNTHESIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CANCER RESEARCH; CANCER STEM CELL; CATABOLISM; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; MOLECULAR DYNAMICS; NONHUMAN; POLYAMINE HOMEOSTASIS; POLYAMINE METABOLISM; REVIEW; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; FEMALE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOGENIC POLYAMINES; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84911983994     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3156-7     Document Type: Review

References (134)

1. Rea G, Bocedi A, Cervelli M (2004) Question: what is the biological function of the polyamines? IUBMB Life 56:167–169
2. Amendola R, Cervelli M, Fratini E, Polticelli F, Sallustio DE, Mariottini P (2009) Spermine metabolism and anticancer therapy. Curr Cancer Drug Targets 9:118–130
3. Nowotarski SL, Woster PM, Casero RA Jr (2013) Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 15:e3
4. Russell D, Snyder SH (1968) Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci USA 60:1420–1427
5. Thomas T, Thomas TJ (2003) Polyamine metabolism and cancer. J Cell Mol Med 7:113–126
6. Wallace HM, Duthie J, Evans DM, Lamond S, Nicoll KM, Heys SD (2000) Alterations in polyamine catabolic enzymes in human breast cancer tissue. Clin Cancer Res 6:3657–3661
7. Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4:781–792
8. Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6:373–390
9. Cervelli M, Angelucci E, Germani F, Amendola R, Mariottini P (2014) Inflammation, carcinogenesis and neurodegeneration studies in transgenic animal models for polyamine research. Amino Acids 46:521–530
10. Pegg AE, Casero RA (2011) Current status of the polyamine research field. Methods Mol Biol 720:3–35
11. Cervelli M, Amendola R, Polticelli F, Mariottini P (2012) Spermine oxidase: ten years after. Amino Acids 42:441–450
12. Capone C, Cervelli M, Angelucci E, Colasanti M, Macone A, Mariottini P, Persichini T (2013) A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity. Free Radic Biol Med 63:99–107
13. Cervelli M, Bellavia G, D’Amelio M, Cavallucci V, Moreno S, Berger J, Nardacci R, Marcoli M, Maura G, Piacentini M, Amendola R, Cecconi F, Mariottini P (2013) A new transgenic mouse model for studying the neurotoxicity of spermine oxidase dosage in the response to excitotoxic injury. PLoS One 8:e64810
14. Cervelli M, Angelucci E, Stano P, Leboffe L, Federico R, Antonini G, Mariottini P, Polticelli F (2014) The Glu216–Ser218 pocket is a major determinant of spermine oxidase substrate specificity. Biochem J 463:453–459
15. Manni A, Badger B, Luk G, Wright C, Caplan R, Rockette H, Bartholomew M, Ahmed SR (1988) Role of polyamines in the growth of hormone-responsive experimental breast cancer In vivo. Breast Cancer Res Treat 11:231–240
16. Manni A, Badger B, Lynch J, Demers L (1990) Selectivity of polyamine involvement in hormone action on normal and neoplastic target tissues of the rat. Breast Cancer Res Treat 17:187–196
17. Glikman P, Manni A, Demers L, Bartholomew M (1989) Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res 49:1371–1376
18. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059–2069
19. Manni A, Grove R, Kunselman S, Aldaz CM (1995) Involvement of the polyamine pathway in breast cancer progression. Cancer Lett 92:49–57
20. Glikman PL, Manni A, Bartholomew M, Demers L (1990) Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J Steroid Biochem Mol Biol 37:1–10
21. Thomas T, Thomas TJ (1994) Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat 29:189–201
22. Shah N, Thomas T, Shirahata A, Sigal LH, Thomas TJ (1999) Activation of nuclear factor kappaB by polyamines in breast cancer cells. Biochemistry 38:14763–14774
23. Balabhadrapathruni S, Santhakumaran LM, Thomas TJ, Shirahata A, Gallo MA, Thomas T (2005) Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells. Oncol Rep 13:101–108
24. Faaland CA, Thomas TJ, Balabhadrapathruni S, Langer T, Mian S, Shirahata A, Gallo MA, Thomas T (2000) Molecular correlates of the action of bis(ethyl)polyamines in breast cancer cell growth inhibition and apoptosis. Biochem Cell Biol 78:415–426
25. Cervelli M, Bellavia G, Fratini E, Amendola R, Polticelli F, Barba M, Federico R, Signore F, Gucciardo G, Grillo R, Woster PM, Casero RA Jr, Mariottini P (2010) Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm. BMC Cancer 10:555
26. Seiler N (2003) Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4:537–564
27. Amendola R, Cervelli M, Fratini E, Sallustio DE, Tempera G, Ueshima T, Mariottini P, Agostinelli E (2014) Reactive oxygen species spermine metabolites generated from amine oxidases and radiation represent a therapeutic gain in cancer treatments. Int J Oncol 43:813–820
28. Amendola R, Cervelli M, Tempera G, Fratini E, Varesio L, Mariottini P, Agostinelli E (2014) Spermine metabolism and radiation-derived reactive oxygen species for future therapeutic implications in cancer: an additive or adaptive response. Amino Acids 46:487–498
29. Schipper RG, Penning LC, Verhofstad AA (2000) Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin Cancer Biol 10:55–68
30. Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2:244–258
31. Schuber F (1989) Influence of polyamines on membrane functions. Biochem J 260:1–10
32. Feuerstein BG, Williams LD, Basu HS, Marton LJ (1991) Implications and concepts of polyamine–nucleic acid interactions. J Cell Biochem 46:37–47
33. Matthews HR (1993) Polyamines, chromatin structure and transcription. BioEssays 15:561–566
34. Pegg AE (2009) Mammalian polyamine metabolism and function. IUBMB Life 61:880–894
35. Wallace HM (2000) The physiological role of the polyamines. Eur J Clin Invest 30:1–3
36. Upp JR Jr, Saydjari R, Townsend CM Jr, Singh P, Barranco SC, Thompson JC (1988) Polyamine levels and gastrin receptors in colon cancers. Ann Surg 207:662–669
37. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H (2000) Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60:5125–5133
38. Gilmour SK (2007) Polyamines and nonmelanoma skin cancer. Toxicol Appl Pharmacol 224:249–256
39. Manni A, Astrow SH, Gammon S, Thompson J, Mauger D, Washington S (2001) Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 67:147–156
40. Deng W, Jiang X, Mei Y, Sun J, Ma R, Liu X, Sun H, Tian H, Sun X (2008) Role of ornithine decarboxylase in breast cancer. Acta Biochim Biophys 40:235–243
41. Manni A, Mauger D, Gimotty P, Badger B (1996) Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 2:1901–1906
42. Glikman P, Vegh I, Pollina MA, Mosto AH, Levy CM (1987) Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 60:2237–2243
43. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G (1989) Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171
44. Perez G, Olivares IM, Rodriguez MG, Ceballos GM, Garcia Sanchez JR (2012) Arginase activity in patients with breast cancer: an analysis of plasma, tumors, and its relationship with the presence of the estrogen receptor. Onkologie 35:570–574
45. 2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem 280:39843–39851
46. 1-acetyltransferase—the turning point in polyamine metabolism. FASEB J 7:653–661
47. Tavladoraki P, Cervelli M, Antonangeli F, Minervini G, Stano P, Federico R, Mariottini P, Polticelli F (2011) Probing mammalian spermine oxidase enzyme-substrate complex through molecular modeling, site-directed mutagenesis and biochemical characterization. Amino Acids 40:1115–1126
48. Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine backconversion. Biochem J 370(Pt 1):19–28
49. Polticelli F, Salvi D, Mariottini P, Amendola R, Cervelli M (2012) Molecular evolution of the polyamine oxidase gene family in Metazoa. BMC Evol Biol 12:90
50. Cervelli M, Salvi D, Polticelli F, Amendola R, Mariottini P (2013) Structure–function relationships in the evolutionary framework of spermine oxidase. J Mol Evol 76:365–370
51. Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367(Pt 3):665–675
52. Cervelli M, Polticelli F, Federico F, Mariottini P (2003) Heterologous expression and characterization of mouse spermine oxidase. J Biol Chem 278:5271–5276
53. Cervelli M, Bellini A, Bianchi M, Marcocci L, Nocera S, Polticelli F, Federico R, Amendola R, Mariottini P (2004) Mouse spermine oxidase gene splice variants. Nuclear subcellular localization of a novel active isoform. Eur J Biochem 271:760–770
54. Casero RA Jr, Pegg AE (2009) Polyamine catabolism and disease. Biochem J 421:323–338
55. Babbar N, Casero RA Jr (2006) Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66:11125–11130
56. Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, Casero RA Jr (2011) Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis induced colon tumorigenesis. Proc Natl Acad Sci USA 108:15354–15359
57. Bana E, Bagrel D (2011) In vitro breast cancer models as useful tools in therapeutics? In: Gunduz M, Gunduz E (eds), Breast cancer focusing tumor microenvironment, stem cells and metastasis, chapter 2. Publisher InTech, pp 21–38
58. Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13:215
59. Lacroix M (2008) Persistent use of “false” cell lines. Int J Cancer 122:1–4
60. Cohen FJ, Manni A, Glikman P, Bartholomew M, Demers L (1988) Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. Cancer Res 48:6819–6825
61. Kim I, Manni A, Lynch J, Demers L (1991) Polyamine involvement in the secretion and action of TGF-alpha in hormone sensitive human breast cancer cells in culture. Breast Cancer Res Treat 18:83–91
62. Manni A, Badger B, Grove R, Kunselman S, Demers L (1995) Isolation and characterization of human breast cancer cells overexpressing S-adenosylmethionine decarboxylase. Cancer Lett 95:23–28
63. Manni A, Badger B, Wechter R, Kunselman S, Rossini A, Demers L (1995) Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48664 in malignant and immortalized normal human breast epithelial cells in culture. Int J Cancer 62:485–491
64. Thomas T, Faaland CA, Adhikarakunnathu S, Thomas TJ (1996) Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 139:293–306
65. Manni A, Wechter R, Grove R, Wei L, Martel J, Demers L (1995) Polyamine profiles and growth properties of ornithine decarboxylase overexpressing MCF-7 breast cancer cells in culture. Breast Cancer Res Treat 34:45–53
66. Manni A, Wechter R, Gilmour S, Verderame MF, Mauger D, Demers LM (1997) Ornithine decarboxylase over-expression stimulates mitogen-activated protein kinase and anchorage-independent growth of human breast epithelial cells. Int J Cancer 70:175–182
67. Zaletok S, Alexandrova N, Berdynskykh N, Ignatenko N, Gogol S, Orlovsky O, Tregubova N, Gerner E, Chekhun V (2004) Role of polyamines in the function of nuclear transcription factor NF-κB in breast cancer cells. Exp Oncol 26:221–225
68. Pavlov V, Rodilla V, Kong Thoo Lin P (2002) Growth, morphological and biochemical changes in oxa-spermine derivative-treated MCF-7 human breast cancer cells. Life Sci 71:1161–1173
69. Pavlov V, Lin PK, Rodilla V (2002) Biochemical effects and growth inhibition in MCF-7 cells caused by novel sulphonamido oxa-polyamine derivatives. Cell Mol Life Sci 59:715–723
70. Zhu Q, Jin L, Casero RA Jr, Davidson NE, Huang Y (2012) Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. Breast Cancer Res Treat 136:57–66
71. Arisan ED, Obakan P, Coker A, Palavan-Unsal N (2012) Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells. Mol Med Rep 5:1323–1329
72. Obakan P, Arısan ED, Özfiliz P, Çoker-Gürkan A, Palavan-Ünsal N (2014) Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. Mol Biol Rep 41:145–154
73. Bey P, Bolkenius FN, Seiler N, Casara P (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28:1–2
74. 1-bis(2,3-butadienyl)-1,4-butanediamine. Biochem Biophys Res Commun. 322:1–8
75. Bianchi M, Bellini A, Cervelli M, Degan P, Marcocci L, Martini F, Scatteia M, Mariottini P, Amendola R (2007) Chronic sub-lethal oxidative stress by spermine oxidase overactivity induces continuous DNA repair and hypersensitivity to radiation exposure. Biochim Biophys Acta 1773:774–783
76. Holst CM, Johansson VM, Alm K, Oredsson SM (2008) Novel anti-apoptotic effect of Bcl-2: prevention of polyamine depletion-induced cell death. Cell Biol Int 32:66–74
77. Nair SK, Verma A, Thomas TJ, Chou TC, Gallo MA, Shirahata A, Thomas T (2007) Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett 250:311–322
78. Pledgie-Tracey A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA Jr, Davidson NE (2010) The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic eVects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol 65:1067–1081
79. Saab MH, West EE, Bieszk NC, Preuss C, Mank AR, Casero RA Jr, Woster PM (1993) Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine-N1-acetyltransferase (SSAT) and as potential anti-tumor agents. J Med Chem 36:2998–3004
80. Casero RA Jr, Mank AR, Saab NH, Wu R, Dyer WJ, Woster PM (1995) Growth and biochemical effects of unsymmetrically substituted polyamine analogues in human lung tumor cells 1. Cancer Chemother Pharmacol 36:69–74
81. McCloskey DE, Casero RA Jr, Woster PM, Davidson NE (1995) Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res 55:3233–3236
82. Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA Jr (1999) Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 6:69–73
83. Varghese S, Gupta D, Baran T, Jiemjit A, Gore SD, Casero RA Jr, Woster PM (2005) Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors. J Med Chem 48:6350–6365
84. Varghese S, Senanayake T, Murray-Stewart T, Doering K, Fraser A, Casero RA Jr, Woster PM (2008) Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J Med Chem 51:2447–2456
85. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr (2007) Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104:8023–8028
86. Wu Y, Steinbergs N, Murray-Stewart T, Marton LJ, Casero RA Jr (2012) Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Biochem J 442:693–701
87. Hahm HA, Dunn VR, Butash KA, Deveraux WL, Woster PM, Casero RA Jr, Davidson NE (2001) Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7:391–399
88. Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA Jr, Marton LJ, Cleveland JL (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res 68:4783–4790
89. Hacker A, Marton LJ, Sobolewski M, Casero RA Jr (2008) In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 63:45–53
90. Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM (2010) Reduction of the putative CD44 + CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Anticancer Drugs 21:897–906
91. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr (2012) Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 42:887–898
92. Silva TM, Fiuza SM, Marques MPM, Persson L, Oredsson S (2014) Increased breast cancer cell toxicity by palladination of the polyamine analogue N1, N11-bis(ethyl)norspermine. Amino Acids 46:339–352
93. Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131–146
94. Esteban-Fernández D, Moreno-Gordaliza E, Cañas B, Palacios MA, Gómez-Gómez MM (2010) Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. Metallomics 2:19–38
95. Silva TM, Andersson S, Sukumaran SK, Marques MP, Persson L, Oredsson S (2013) Norspermidine and novel Pd(II) and Pt(II) polynuclear complexes of norspermidine as potential antineoplastic agents against breast cancer. PLoS ONE 8(2):e55651
96. Silva TM, Oredsson S, Persson L, Woster P, Marques MP (2012) Novel Pt(II) and Pd(II) complexes with polyamine analogues: synthesis and vibrational analysis. J Inorg Biochem 108:1–7
97. Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A (2008) Effects of polyamine depletion by α-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 107:33–40
98. Shah N, Antony T, Haddad S, Amenta P, Shirahata A, Thomas TJ, Thomas T (1999) Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice. Cancer Lett 146:15–23
99. Manni A, Badger B, Martel J, Demers L (1992) Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice. Cancer Lett 66:1–9
100. Thomas T, Shah N, Faaland C, Gallo M, Yurkow E, Satyaswaroop P (1997) Effects of a bis(benzyl)spermine analog on MCF-7 breast cancer cells in culture and nude mice xenografts. Oncol Rep 4:5–13
101. Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP (2000) Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. Anticancer Res 20:97–101
102. Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR (2002) Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19:95–105
103. Prakash NJ, Schechter PJ, Grove J, Koch-Weser J (1978) Effect of alphadifluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice. Cancer Res 38:3059–3062
104. Herrmann AL, Nelson FR, Slaga TJ (1982) Alphadifluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79:6028–6032
105. Mamont PS, Duchesne MC, Grove J, Bey P (1978) Anti-proliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Comm 81:58–66
106. Herr HW, Warrel RP, Burchenal JH (1986) Phase I trial of α-difluoromethylornithine (DFMO) and methylglyoxal bis(guanylhydrazone) (MGBG) in patients with advanced prostatic cancer. Urology 28:508–511
107. Meyskens FL Jr, Kingsley EM, Glattke T, Loescher L, Booth A (1986) A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4:257–262
108. Horn Y, Schechter PJ, Marton LJ (1987) Phase I-II clinical trial with α-difluoromethylornithine—an inhibitor of polyamine biosynthesis. Eur J Cancer Clin Oncol 23:1103–1107
109. Ganju V, Edmonson JH, Buckner JC (1994) Phase I study of combined α interferon, -difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12:25–27
110. Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K (1998) Phase I dose de-escalation trial of -difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4:303–310
111. O’Shaughnessy JA, Demers LM, Jones SE, Arsenau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A (1999) α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 5:3438–3444
112. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77
113. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8:3105–3117
114. Levin VA, Hess KR, Choucair A, Flynn P, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination -difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990
115. Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O’Brien TG (2006) Combination therapy with 2-difluoromethylornithine and a polyamone transport inhibitor against murine squamous cell carcinoma. Int J Cancer 118:2344–2349
116. Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W (1998) Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90:1212–1218
117. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32–38
118. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17:292–299
119. Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M (1992) Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84:1432–1437
120. Porter CW, Bergeron RJ (1988) Regulation of polyamine biosynthetic activity by spermidine and spermine analogs, a novel antiproliferative strategy. Adv Exp Med Biol 250:677–690
121. Casero RA Jr, Woster PM (2001) Terminally alkylated polyamine analogues as chemotherapeutic agents. J Med Chem 44:1–26
122. Casero RA Jr, Woster PM (2009) Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 52:4551–4573
123. Casero RA Jr, Gabrielson EW, Pegg AE (1994) Immunohistochemical staining of human spermidine/spermine N1-acetyltransferase superinduced in response to treatment with antitumor polyamine analogues. Cancer Res 54:3955–3958
124. Gabrielson EW, Pegg AE, Casero RA Jr (1999) The induction of spermidine/spermine N1-acetyltransferase (SSAT) is a common event in the response of human primary non-small cell lung carcinomas to exposure to the new antitumor polyamine analogue N1, N11-bis(ethyl)norspermine. Clin Cancer Res 5:1638–1641
125. Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW (1995) Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin Cancer Res 1:847–857
126. Streiff RR, Bender JF (2001) Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest New Drugs 19:29–39
127. Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RA Jr, Davidson NE (2003) A phase II study of the polyamine analog N1, N11-diethylnorspermine (DENSPM) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9:5922–5928
128. Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E, Raghavan D (1997) Unusual central nervous system toxicity in a Phase I study of N1, N11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 15:227–234
129. Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L (2004) Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1, N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 3:813–822
130. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M (2005) N1, N12-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res 11:2986–2990
131. Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Zhe Min J, Toyo’oka T (2013) High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem 85:11835–11842
132. Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000) Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319–38328
133. Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60
134. Dong Y, Zhu Y, Jing L, Zhou Q, Wu C, Oupický D (2012) Synthesis of bisethylnorspermine lipid prodrug as gene delivery vector targeting polyamine metabolism in breast cancer. Mol Pharm 4:1654–1664